A Phase 3 interventional study of Aflibercept in Macular Degeneration, Wet Macular Degeneration and Retinal Degeneration, sponsored by Centre Hospitalier Intercommunal Creteil. Completed at 9 sites in France. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Centre Hospitalier Intercommunal Creteil · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Wet Macular Degeneration with a site in France — 2 open to participants now, 4 under way, 3 of them phase 3. Wet Macular Degeneration · France.
Among the 13 studies in Wet Macular Degeneration with a site in France, this one is the 9th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2013, is one of 8 in phase 3, and was the 1st registered.
93 studies on the registry are indexed under Wet Macular Degeneration; 10 are open to participants now.
Browse Wet Macular Degeneration studies →2 of the 13 studies in Wet Macular Degeneration with a site in France are open now. Recruiting first, the newest first:
EyeBiotech Ltd. · Sites in France, United States, Austria and 10 more countries
Ages 50+
4D Molecular Therapeutics · Sites in France, United States, Argentina and 14 more countries
Ages 50+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 8 Wet Macular Degeneration studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 9
First in 2013; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 84 is below the median of 101 across 74 interventional studies indexed under Wet Macular Degeneration.
Median enrollment 569 across the 10 interventional studies, 236 across the 3 observational. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 13 have an industry lead sponsor. The 9 most frequent:
Centre Hospitalier Intercommunal Creteil is the lead sponsor of 132 studies on the registry; 37 are open to participants now.
Centre Hospitalier Intercommunal Creteil has 2 studies filed under Wet Macular Degeneration — fewer than ten, so there is no comparison to draw.
1 of the studies in Wet Macular Degeneration with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07064759Phase 34D Molecular TherapeuticsSingle Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Wet Macular Degeneration with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the current study is to evaluate the ability of Eylea to induce a regression of PED height on patients previously extensively treated by Lucentis.
The regimen proposed for this study is the 3 monthly injection followed by a 6 weeks interval injection until week 26.
The regimen proposed for this study is the 3 monthly injection followed by a 6 weeks interval injection until week 26.
93 studies on the registry are indexed under Wet Macular Degeneration; 10 are open to participants now.
This study's enrollment of 84 is below the median of 101 across 74 interventional studies indexed under Wet Macular Degeneration.
Browse Wet Macular Degeneration studies →Centre Hospitalier Intercommunal Creteil is the lead sponsor of 132 studies on the registry; 37 are open to participants now.
Compared within Wet Macular Degeneration, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive 2 mg of aflibercept by intravitreal injection every 4 weeks until week 8, followed by every 6 weeks to week 26
Drug: Aflibercept
Intravitreal Injection
Also known as: Eylea, BAY86-5321
Change From Baseline in Maximal Height of Pigment Epithelium Detachment (PED) at 12 Weeks
Time frame: Baseline and 12 weeks
Change From Baseline in Central Retinal Thickness by SD OCT at 12 Weeks
Time frame: Baseline and 12 weeks
Best-corrected Visual Acuity at 12 Weeks
Best-corrected visual acuity (BCVA) was measured using ETDRS letter scores.
Time frame: 12 weeks
Pigment Epithelial Detachment Volume at 12 Weeks
Pigment epithelial detachment volume was assessed by SD-OCT and semiautomated volumetric analysis.
Time frame: 12 weeks
Central Retinal Thickness at 32 Weeks
Time frame: 32 weeks
Pigment Epithelium Detachment Height at 32 Weeks
Time frame: 32 weeks
Visual Acuity at 32 Weeks
Time frame: 32 weeks
Volume of Pigment Epithelium Detachment at 32 Weeks
Time frame: 32 weeks
Pigment Epithelium Detachment Height at 12 Weeks
Maximal pigment epithelial detachment (PED) height was assessed by spectral-domain optical coherence tomography (SD-OCT).
Time frame: Week 12
| Milestone | Aflibercept |
|---|---|
| Started | 84 |
| Completed | 83 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
| micrometers | Aflibercept |
|---|---|
| Change From Baseline in Maximal Height of Pigment Epithelium Detachment (PED) at 12 Weeks | -81.29 (-101.3 to -61.3) |
| micrometers | Aflibercept |
|---|---|
| Change From Baseline in Central Retinal Thickness by SD OCT at 12 Weeks | -65.82 ± 159.86 |
Best-corrected visual acuity (BCVA) was measured using ETDRS letter scores.
| ETDRS letters | Aflibercept |
|---|---|
| Best-corrected Visual Acuity at 12 Weeks | 68.4 ± 14.8 |
Pigment epithelial detachment volume was assessed by SD-OCT and semiautomated volumetric analysis.
| mm^3 | Aflibercept |
|---|---|
| Pigment Epithelial Detachment Volume at 12 Weeks | 0.95 ± 0.85 |
| micrometers | Aflibercept |
|---|---|
| Central Retinal Thickness at 32 Weeks | 387.42 ± 161.34 |
| micrometers | Aflibercept |
|---|---|
| Pigment Epithelium Detachment Height at 32 Weeks | 288.22 ± 123.53 |
| ETDRS letters | Aflibercept |
|---|---|
| Visual Acuity at 32 Weeks | 69.5 ± 14 |
| mm^3 | Aflibercept |
|---|---|
| Volume of Pigment Epithelium Detachment at 32 Weeks | 1 ± 0.87 |
Maximal pigment epithelial detachment (PED) height was assessed by spectral-domain optical coherence tomography (SD-OCT).
| micrometers | Aflibercept |
|---|---|
| Pigment Epithelium Detachment Height at 12 Weeks | 266.04 ± 114.56 |
Collected over Baseline to Week 32. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aflibercept | 0/84 (0%) | 4/84 (4.8%) | 0/84 (0%) |
| Event | Aflibercept |
|---|---|
| Cardiovascular disordersCardiac disorders | 3/84 |
| Confused stateEye disorders | 1/84 |
| Event | Aflibercept |
|---|---|
| Other serious adverse eventsEye disorders | 0/84 |
Baseline characteristics were analyzed in the intention-to-treat population, including all 84 enrolled participants who completed at least one follow-up visit after enrollment.
| Age, Categorical(Participants) | Aflibercept |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 1 |
| >=65 years | 83 |
| Age, Continuous(years) | Aflibercept |
|---|---|
| Mean | 80.5 ± 7.1 |
| Sex: Female, Male(Participants) | Aflibercept |
|---|---|
| Female | 59 |
| Male | 25 |
| Race and Ethnicity Not Collected(Participants) | Aflibercept |
|---|
| Region of Enrollment(Participants) | Aflibercept |
|---|---|
| France | 84 |
The record gives a start of Dec 2013, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2026, 10 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept
Centre Hospitalier Intercommunal Creteil →